Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats
The tyrosine kinase inhibitor sorafenib is the first-line treatment for patients with hepatocellular carcinoma (HCC), in which hyperlipidemia and type 2 diabetes mellitus (T2DM) may often coexist. Protein transporters like organic cation (OCT) and multidrug and toxin extrusion (MATE) are involved in...
Main Authors: | Agnieszka Karbownik, Danuta Szkutnik-Fiedler, Andrzej Czyrski, Natalia Kostewicz, Paulina Kaczmarska, Małgorzata Bekier, Joanna Stanisławiak-Rudowicz, Marta Karaźniewicz-Łada, Anna Wolc, Franciszek Główka, Edmund Grześkowiak, Edyta Szałek |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-06-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/12/7/600 |
Similar Items
-
In vivo assessment of potential for UGT-inhibition-based drug-drug interaction between sorafenib and tapentadol
by: Agnieszka Karbownik, et al.
Published: (2020-10-01) -
Sorafenib-induced pemphigus vulgaris
by: Ajay Deshpande
Published: (2016-01-01) -
Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma
by: Ting Sun, et al.
Published: (2017-11-01) -
Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma
by: Anne Clavreul, et al.
Published: (2018-01-01) -
Triclosan treatment decreased the antitumor effect of sorafenib on hepatocellular carcinoma cells
by: Wu M, et al.
Published: (2018-05-01)